Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check3 days agoChange DetectedRevision tag updated from v3.5.4 to v3.5.5, reflecting a new release version displayed on the page. The update is administrative and does not change study data, eligibility criteria, or how users interact with the page.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page revision stamp changed from v3.5.3 to v3.5.4, indicating a small patch or metadata update rather than a substantive change to the page content.SummaryDifference0.0%

- Check39 days agoChange DetectedA new publication citation has been added to the Publications section: Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, Verzoni E. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. Oncologist. 2024 Mar 4;29(3):254-262. doi: 10.1093/oncolo/oyad348. This update expands the study's literature references related to outcomes in relapsed/refractory RCC treated with tivozanib.SummaryDifference0.0%

- Check46 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3, reflecting a general site release without altering the underlying study information.SummaryDifference0.0%

- Check53 days agoChange DetectedRegional names Královéhradecký kraj and Olomoucký kraj were updated to Hradec Králové Region and Olomouc Region, respectively, with the corresponding addresses adjusted. The revision tag was updated to v3.5.2.SummaryDifference0.1%

- Check67 days agoChange DetectedAdded Padova, Italy, 35128 and removed Padua, Italy, 35128 from the locations list.SummaryDifference0.0%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.